Acular (ketorolac tromethamine ophthalmic solution) 0.5%
Company: AllerganApproval Status: Approved November 1997
Treatment for: post-surgical inflammation following cataract extraction
Areas: Eye Health / Ophthalmology
Possible similar drugs: Acular
| General Information | Side Effects | Mechanism of Action |
General Information
Acular has now been approved by the FDA for post-surgical inflammation following cataract extraction. Acular is administered between one and four times daily starting 24 hours after surgery for two weeks. It can be used with antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. For itch, Acular is administered between one and four times daily as needed.
Side Effects
Adverse events include transient stinging and burning upon application.
Mechanism of Action
Acular (ketorolac tromethamine ophthalmic solution 0.5%) works by inhibiting prostaglandins in the aqueous humor. Allergan began marketing Acular in 1992 to treat seasonal conjunctival allergies, although the drug did find off-label uses for cystoid macular edemas and post-surgical inflammation.
Acular Drug Information
The Acular drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
